Search results
Results from the WOW.Com Content Network
Spravato’s approval for standalone use is based on a study in which patients treated with the therapy showed a rapid and superior improvement in severity of depressive episodes, compared to placebo.
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in people who have not responded to at least two oral antidepressants.
Epclusa, Sofosvel, Velpanat (all in combination with sofosbuvir) Routes of administration: Oral : ATC code: J05AP55 ... CAS Number: 1377049-84-7; PubChem CID: 67683363;
Sofosbuvir/velpatasvir, sold under the brand name Epclusa among others, is a fixed-dose combination medication for the treatment of hepatitis C in adults. [ 2 ] [ 5 ] [ 6 ] [ 7 ] It combines sofosbuvir and velpatasvir .
FDA approves Johnson & Johnson’s ketamine-derived nasal spray for depression as standalone treatment. Beth Greenfield. January 22, 2025 at 8:28 PM ... Spravato is made from esketamine, ...
[64] [65] Johnson & Johnson filed a Food and Drug Administration (FDA) New Drug Application (NDA) for approval on 4 September 2018; [67] the application was endorsed by an FDA advisory panel on 12 February 2019, and on 5 March 2019, the FDA approved esketamine, in conjunction with an oral antidepressant, for the treatment of depression in ...
Esketamine (CLE-100) – ionotropic glutamate NMDA receptor antagonist and dissociative hallucinogen – major depressive disorder – Clexio Biosciences [14] GM-2505 – serotonin 5-HT 2A and 5-HT 2C receptor agonist, psychedelic hallucinogen, and serotonin releasing agent – major depressive disorder – Gilgamesh Pharmaceuticals [ 15 ]
Esketamine is the molecular mirror image of the sedative ketamine, often prescribed off-label for severe cases of depression involving the risk of suicide. FDA Panel Nod for J&J's Esketamine Is ...